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Abstract
Phaeochromocytomas are rare neuroendocrine tumors of the adrenal. They are a very rare cause of 
secondary hypertension. They are very rare in pregnancy and much more so in early pregnancy. In this 
narrative review, we conducted a MEDLINE search of review articles on phaeochromocytoma from 2000 
to 2018 using the key words “phaeochromocytoma, early pregnancy, hypertension, catecholamines, and 
chromaffin tumors. We identified relevant articles and also looked up key references. We also highlight 
the challenges and limitations of our management experience in our practice setting. Although 
phaeochromocytomas are very rare in early pregnancy, a high index of suspicion is needed to make this 
diagnosis. Otherwise, it may be misdiagnosed as pregnancy induced or related hypertension. 
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RAPPORT DE CAS
Phaéochromocytome en début de grossesse: rapport de cas et revue de 
la littérature.
Resume
Les phéochromocytomes sont des tumeurs neuroendocrines rares de la surrénale. Ils sont une cause très 
rare d'hypertension secondaire. Ils sont très rares pendant la grossesse et beaucoup plus en début de 
grossesse. Dans cette revue narrative, nous avons effectué une recherche dans MEDLINE d'articles de 
synthèse sur le phaéochromocytome de 2000 à 2018 en utilisant les mots clés «phaeochromocytome, 
début de grossesse, hypertension, catécholamines et tumeurs à chromaffine. Nous avons identifié des 
articles pertinents et avons également recherché des références clés. Nous soulignons également les défis 
et les limites de notre expérience de gestion dans notre milieu de travail. Bien que les phéochromocytomes 
soient très rares en début de grossesse, un indice de suspicion élevé est nécessaire pour poser ce diagnostic. 
Sinon, il peut être mal diagnostiqué comme une hypertension liée à la grossesse ou une hypertension 
associée.
Mots-clés: Phaéochromocytome, grossesse précoce, hypertension, catécholamines, tumeurs 
chromaffines
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INTRODUCTION
P h a e o c h r o m o c y t o m a s  a r e  
neuroendocrine catecholamine producing tumors 
(1). They occur in one or both adrenal glands, the 
rest occurring in the sympathetic ganglia (2). 
They account for 3-8 % of all incidental adrenal 
masses (3,4,5). Its incidence is less than 0.2 per 
10,000 pregnancies (6). It has an incidence of 2-8 
cases per million per year in the general 
p o p u l a t i o n  ( 7 ) .  T h e  p r e v a l e n c e  o f  
Pheochromocytoma in hypertensive patients is 
about 0.2 -0.4%, however, in term pregnancies it 
is estimated at 0.002% (8). It is a rare but 
important cause of secondary hypertension in 
p r e g n a n c y  ( 9 ) .  T h e  p r e v a l e n c e  o f  
Phaeochromocytoma in pregnancies carried to 
term is 1 in 50, 000 – 54, 000 (10,11).
About one-quarter of these tumors arise 
from genetic mutations (10,11). Genes mutations 
i m p l i c a t e d  i n  t h e  f o r m a t i o n  o f  
Phaeochromocytoma include succinate 
dehydrogenase subunit B (SDHB) gene and 
succinate dehydrogenase subunit D (SDHD) 
gene, SDHD (12). Some of these tumors are 
associated with von Hippel-Lindau (VHL) 
disease, multiple endocrine neoplasia type II 
(MEN II) and neurofibromatosis type I (13).
The clinical manifestations of these 
tumors are due to the array of hormones they 
produce:  dopamine ,  ep inephr ine  and 
norepinephrine. Norepinephrine is the dominant 
hormone, and is responsible for the sustained or 
paroxysmal hypertension with episodes of 
hypotension. Dopamine secreting tumors present 
with hypotension or normotension. Epinephrine 
producing tumors can cause vasodilatation and 
shock (14,15). In most patients, the clinical 
manifestations are accounted for by contributions 
f r o m  t h e s e  t h r e e  h o r m o n e s  ( 1 6 )  
Phaeochromocytomas also produce ectopic 
hormones such as gastrin, serotonin, vasoactive 
intestinal peptide, adrenocorticotropic hormone, 
substance P, somatostatin, and calcitonin. This 
explains the wide array of symptomatology and 
also why it may pose a diagnostic challenge 
( 1 1 7 , 1 8 ) .  O n l y  a b o u t  5 0 %  o f  
phaeochromocytomas are symptomatic. Most are 
discovered as incidental adrenal masses or are 
found during autopsy (19).
The purpose of this review is to describe 
a rare case of phaeochromocytoma seen in early 
pregnancy and also to review the existing 
literature. Finally, we highlight our management 
experience and the challenges we faced in our 
practice setting.
CASE REPORT
Mrs. F H is a 32-year-old gravida4 
+2
Para1 (1 alive) trader who was rushed in to the 
accident and emergency unit of the University of 
Port Harcourt Teaching Hospital at 13 weeks of 
gestation. She presented with a history of fainting 
attack of 12 hours duration associated with 
nausea and vomiting, persisting headache and 
generalized body weakness. She also complained 
of episodes of short-lasting paroxysmal 
palpitations and sweating. There was no history 
of orthopnea, paroxysmal nocturnal dyspnea or 
leg swelling. She had no vaginal bleeding or 
urinary symptoms. She was not a known 
hypertensive or diabetic prior to index pregnancy. 
One week prior to her presentation, she was 
admitted into the gynecological ward and was 
managed for threatened miscarriage. Her only 
confinement was 2 years prior to index 
pregnancy.  She had emergency caesarean 
section for severe pre-eclampsia at 36weeks 
gestation with good fetal outcome. Her blood 
pressure had normalized prior to discharge 5 days 
after the delivery. 
Past surgical history revealed an ovarian 
cystectomy which was done five years ago. Her 
brother  died of  hypertension related 
complications several years ago. She neither took 
alcohol nor tobacco in any form.
Her general physical examination was 
2
normal save for a body mass index of 26.4 kg/m . 
Cardiovascular system examination showed a 
tachycardia of 100/min with a blood pressure of 
210/120 mmHg. Abdominal examination 
revealed a midline sub-umbilical scar, a fundal 
height of 22/52 weeks and no organomegaly. 
Other systems examination was normal. A 
provisional diagnosis of labile hypertension in 
pregnancy was made. Differential diagnoses 
considered were phaeochromocytoma; thyroid 
disease and molar pregnancy. Urinalysis was 
normal. Full blood count showed a packed cell 
volume of 31.0 % but other parameters were 
within normal limits. Serum electrolyte, urea, 
creatinine and uric acid were also within the 
normal range. Abdomino-pelvic ultrasound scan 
showed intrauterine singleton active fetus with 
good cardiac activity at 13 weeks gestation co-
existing with multiple uterine fibroids. There was 
an iso-echoic mass closely related to the liver at 
the point of entry of the inferior vena cava 
measuring 5.9 cm by 5.2 cm diameter. Twenty 
four-hour urine normetanephrine was markedly 
elevated at 62, 984.0 nmol/24 hours (573.0 -1, 
932.0 nmol/24 hours). Normetanephrine-
creatinine ratio was 4,738: 1 (26 -200: 1). Serum 
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T3/T4 levels were normal. Magnetic resonance 
imaging of her abdomen was not done due to 
financial constraints. A definitive diagnosis of 
Pheochromocytoma in pregnancy was made. She 
was counseled on her condition, its complications 
and the management options.
A pointer to her diagnosis was the sudden 
drop in her presenting blood pressure to 80/40 
mmHg, 5 minutes after administration of 20 mg 
of intravenous labetalol. This blood pressure drop 
was followed by paroxysms of fainting. At this 
time, she had now developed cold clammy 
extremities. She was resuscitated with 200ml of 
0.9% normal saline over 10 minutes. Following 
this, her blood pressure suddenly rose to 250/130 
mmHg. Intravenous f luids were thus 
discontinued. She was given prazosin (5mg 
daily), an á selective blocker, and oral nifedipine 1 
(20mg daily) a calcium channel blocker
However, her blood pressure continued to 
fluctuate between 80/20 mmHg and 250/130 
mmHg She kept having paroxysms of severe 
hypertension and hypotension with syncopal 
attacks. A planned laparoscopic exploration was 
not done due to financial constraints. Her 
condition progressively worsened leading to 
medical termination of the pregnancy 6 weeks 
after admission. At cervical assessment, the 
Bishop score was 3, so intracervical extra-
amniotic Foley catheter, size 18FR was passed 
into the uterus and retained with 50mls of sterile 
water for 24 hours. Repeat Bishop score after 
24hours was 5 and the intracervical extra-
amniotic catheter was repeated and removed after 
24hours. The Bishop Score improved to 9 and she 
was having mild lower abdominal pain. An 
intravenous solution of 1Litre Normal saline with 
20 units of oxytocin was commenced at 30dpm to 
induce an maintain intermittent uterine 
contractions. She received 10mg of pethidine and 
25mg of promethazine for pain relief. She also 
continued her anti-hypertensive throughout the 
induction. She expelled a fetus and the placenta 
after 7hours of the induction. The feotus weighed 
215gms. Her systolic blood pressure ranged 
between 160 to 180mmHg and the diastolic blood 
pressure between 95 to 110mmHg during the 
induction. The paroxysms of hypertension and 
hypotension with syncopal attacks reduced 
significantly following termination of her 
pregnancy. She was counseled on contraception 
and discharged to the Surgeons and the 




The diagnosis in the index case was made 
quite early at 13 weeks of gestation, due to the 
paroxysmal nature of her presenting symptoms 
and a high index of suspicion. The symptoms of 
phaeochromocytoma are due to excessive 
synthesis and release into the systemic 
circulation of catecholamines (20). During 
p r e g n a n c y  c o m p l i c a t e d  w i t h  
phaeochromocytoma, there are transient 
excessive maternal levels of catecholamines 
which have deleterious effects on the utero-
placental circulation; this may lead to extreme 
vasoconstriction of the vascular bed and 
subsequent placental abruption and intrauterine 
hypoxia of the fetus as sometimes seen in these 
p a t i e n t s  ( 2 1 ) .  S o m e  p a t i e n t s  w i t h  
pheochromocytoma in pregnancy may be 
asymptomatic. However, some may present as a 
 
life-threatening hypertensive emergency, as was 
the case of this patient. Features may include 
hypertension which may be labile, headache, 
excessive sweating and palpitation as was seen in 
our patient (22). Other reported symptoms in 
these patients include; persisting nausea, 
vomiting, generalized weakness, breathlessness 
and chest pain, photophobia, tinnitus, insomnia, 
weight loss, hyperglycemia and heat intolerance 
 
(23). Others may present with anxiety and 
syncopal attacks as was the case with our patient 
 
(24). Other features which may suggest 
pheochromocytoma are postural hypotension, 
congestive cardiac failure, seizures, visual 
 
disturbances and abdominal pain in pregnancy.
Our patient had postural hypotension and 
abdominal pain.
M a n y  p r e g n a n t  p a t i e n t s  w i t h  
pheochromocytoma become increasingly 
symptomatic with increasing gestational age, 
probably due to the growing size of the uterus, 
movements of the fetus, uterine contractions and 
abdominal palpation. The diagnosis of 
pheochromocytoma in pregnancy is often missed 
because of the varied signs and symptoms that 
may mimic other forms of hypertension in 
pregnancy, including pre-eclampsia (25). Other 
differential diagnoses are thyrotoxicosis/thyroid 
 storm and panic attack. Hence, in making the 
clinical diagnosis of pheochromocytoma in 
pregnancy, a high index of suspicion is required 
as well as carefully obtaining a good history of 
the symptom profile. 
The diagnosis of phaeochromocytoma depends 
on the biochemical demonstration of excessive 
production of catecholamines or their 
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metabolites in the plasma or urine of these 
p a t i e n t s  ( 2 6 ) .  T h e  2 4 - h o u r  u r i n a r y  
catecholamines are highly recommended in 
pregnancy because; pregnancy does not cause 
elevation of urinary catecholamine levels into the 
diagnostic range for pheochromocytoma (27). On 
the other hand, plasma metanephrines as a 
screening test for pheochromocytoma is said to 
have a poor specificity at 85% to 89% (28).
The metanephrines and normetanephrine 
are the O-methylated derivatives of epinephrine 
and norepinephrine respectively. The normal 
values for urinary metanephrines and 
normetanephrine are less than 900 µg per 24-hour 
urine and less than 600 µg per 24-hour urine 
respectively. The index patient had markedly 
elevated normetanephrine of 62,984.0 nmol per 
24-hour urine. Other derivatives of epinephrine 
and norepinephrine which could be assayed as a 
screening test for pheochromocytoma are  
plasma or urine vanylmandelic acid (VMA), 
 
fractionated metanephrines, urinary dopamine 
which was assayed in the past, as well as 
normetanephrine: creatinine ratio (29,30). The 
normetanephrine:creatinine ratio was  found to 
be elevated in this patient. 
After biochemical confirmation of the 
presence of the tumor, the next step is localization 
of the tumor. This is done by performing an 
abdomino-pelvic magnetic resonance imaging 
(MRI) or computerized tomography (CT) scan. 
MRI classically shows a bright-bulb lesion on T2 
comparable to the signal intensity of CSF (31). 
Unlike CT scan, MRI does not expose the fetus to 
radiation (32). CT changes range from areas of 
low to high attenuation (33,34). Abdominal 
ultrasound scan may play a role in localizing the 
tumor (35). 
Functional imaging is indicated if 
123
abdominal imaging studies are negative. I-
123meta-iodobenzylguanidine ( I-MIBG or MIBG) 
is the ligand commonly used for functional 
imaging. MIBG is a norepinephrine analog that is 
taken up by the presynaptic adrenergic nerves and 
sympathomedullary tissue before ending up 
finally in cytoplasmic storage vesicles by an 
active amine uptake system (36). The uptake of 
MIBG is proportional to the number of secretory 
granules within the tumor. Hence, the classic 
appearance of a pheochromocytoma is unilateral 
 focal uptake within the tumor (37,38). Positron 
emission tomography PET is a diagnostic 
modality mostly used in research settings. It is 
limited by its unavailability and cost issues 
(39,40).
T h e  d e f i n i t i v e  t r e a t m e n t  o f  
pheochromocytoma is the surgical excision of the 
tumor once the diagnosis is confirmed. However, 
the timing of surgery during pregnancy is 
controversial and challenging. It may depend on 
 the gestational age at presentation, the clinical 
response to medical treatment, and the presence 
or absence of fetal distress. The management of 
p h e o c h r o m o c y t o m a  i n  p r e g n a n c y  i s  
multidisciplinary and requires the collaboration 
of the cardiologists, endocrinologists, 
obstetricians, paediatricians, anesthesiologists 
and general surgeons to ensure the best outcome 
for mother and baby. We employed a 
multidisciplinary approach in the management of 
this patient.
Good foeto-maternal outcome is best 
achieved by perioperative optimization of the 
 patient. Electrocardiogram, echocardiogram and 
a chest radiograph are mandatory in the pre-
operative evaluation of these patients. 
Electrolytes, urea and creatinine should also be 
performed to assess adequacy of renal function. 
In addition, the control of blood pressure, the 
heart rate and restoration of the blood volume are 
 very important. The aim is to prevent an acute 
hypertensive crisis in the operating room and 
reduce the risk of catecholamine-induced 
hemodynamic changes during anaesthesia and 
surgery and involves the combination of á-
adrenergic blockers and â-blockers. Examples of 
á-adrenergic blockers commonly used are; 
Phenoxybenzamine, a non-selective long acting 
á-adrenergic blocker, and prazosin, a short acting  
á -adrenergic blocker. Dihydropyridine calcium 1
channel blockers such as felodipine may also be 
used alone or in combination with the á -1
adrenergic blockers or as primary treatment of 
hypertension. The side effect of á-adrenergic 
blockers is postural hypotension (41). The 
calcium channel blockers induce minimal 
 hypotension and has the advantage of causing 
smooth muscle relaxation in peripheral and 
coronary arteries, inhibiting the norepinephrine-
stimulated calcium influx into vascular smooth 
muscles (42). Magnesium sulphate can be used 
for pre-operative control of blood pressure in 
patients with pheochromocytoma. It acts by 
modulating adrenergic receptor response to 
catecholamine and also prevents their release 
from the chromaffin cells (43).
The critical period of hemodynamic 
instability intra-operatively are; while moving 
the patient on the table, during induction of 
general anaesthesia, at initiation of mechanical 
ventilation due to raised intra-abdominal 
pressure and while directly manipulating the 
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346(19):1459-66.
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New England Journal of Medicine. 1993; 
329(21):1531-8.
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Decoulx M, Wemeau JL, et al. Dopamine-
secreting pheochromocytoma: an unrecognized 
entity? Classification of pheochromocytomas 
according to their type of secretion. Surgery. 
1986; 100(6):1154-62.
15. Bergland BE. Pheochromocytoma presenting as 
shock. The American Journal of Emergency 
Medicine. 1989; 7(1):44-8.
16. Manger WM. The protean manifestations of 
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34(6):1101-12.
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Medicine. 2001; 134(4):315-29.
20. Prys-Roberts C. Phaeochromocytoma-recent 
progress in its management. British Journal of 
Anaesthesia. 2000; 85(1):44-57.
21. Lenders JW. Endocrine disorders in pregnancy: 
pheochromocytoma and pregnancy: a deceptive 
connection. European Journal of Endocrinology. 
2012; 166(2):143-50.
tumor during surgery. During these critical 
'periods, theres usually a surge of catecholamine 
release and therefore an increase in the arterial 
blood pressure. These however can be limited by 
increased anaesthetic drugs and muscle 
relaxation as well as careful surgical handling of 
the tumor (44,45). Hypertension, following 
pheochromocytoma removal is definitively 
controlled within a few hours to days (46,47). 
Other post-operative complications are rebound 
hypoglycemia secondary to excessive insulin 
secretion and persistent hypertension (48)
T h e  m o r t a l i t y  f r o m  u n d i a g n o s e d  
phaeochromocytoma is very high, about, about 
50%. Most deaths occur during induction of 
labour or vaginal delivery (49). Early diagnosis 
and prompt intervention reduce maternal and 
fetal mortality to <5% and <15% respectively 
(50,51,52).
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CONCLUSION
Pheochromocytoma in early pregnancy 
is life-threatening to mother and foetus, may pose 
diagnostic, therapeutic and management 
dilemmas. However, a high index of suspicion, 
prompt diagnosis, and prompt treatment in a 
multidisciplinary approach may improve foeto- 
maternal outcomes.  
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